tiprankstipranks
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
PremiumPress ReleasesLAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
1M ago
Lava enters collaboration with Merk to evaluate LAVA-1207, KEYTRUDA
PremiumThe Fly
Lava enters collaboration with Merk to evaluate LAVA-1207, KEYTRUDA
3M ago
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
PremiumPress Releases
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
3M ago
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
PremiumPress ReleasesLAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
8M ago
Lava Therapeutics reports Q2 EPS (48c), consensus (47c)
PremiumThe Fly
Lava Therapeutics reports Q2 EPS (48c), consensus (47c)
8M ago
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
PremiumPress Releases
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
8M ago
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
PremiumPress ReleasesLAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
11M ago
LAVA Therapeutics to Participate in the Jefferies Healthcare Conference
PremiumPress Releases
LAVA Therapeutics to Participate in the Jefferies Healthcare Conference
11M ago
LAVA Announces Annual Meeting of Shareholders
PremiumPress Releases
LAVA Announces Annual Meeting of Shareholders
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100